The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $14.76

Today's change+1.51 +11.40%
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $14.76

Today's change+1.51 +11.40%
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc Hits New 20-day High

Sarepta Therapeutics Inc closed up sharply Wednesday, rallying (U.S.)$1.51 or 11.40% to (U.S.)$14.76 and setting a new 20-day high. Over the last five days, shares have gained 13.63%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 70.13% during the last year.

Key company metrics

  • Open(U.S.) $13.97
  • Previous close(U.S.) $13.25
  • High(U.S.) $14.85
  • Low(U.S.) $13.52
  • Bid / Ask-- / --
  • YTD % change+2.00%
  • Volume3,100,679
  • Average volume (10-day)1,100,800
  • Average volume (1-month)891,687
  • Average volume (3-month)843,298
  • 52-week range(U.S.) $11.33 to (U.S.) $36.47
  • Beta1.06
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.38
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue0136
Total other revenue--------
Total revenue0136
Gross profit--------
Total cost of revenue--------
Total operating expense45353331
Selling / general / administrative14131210
Research & development31222121
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0----0
Other operating expenses, total--------
Operating income-45-34-30-25
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-44-29-34-28
Income after tax-44-29-34-28
Income tax, total----00
Net income-44-29-34-28
Total adjustments to net income--------
Net income before extra. items-44-29-34-28
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-44-29-34-28
Inc. avail. to common incl. extra. items-44-29-34-28
Diluted net income-44-29-34-28
Dilution adjustment--000
Diluted weighted average shares41414038
Diluted EPS excluding extraordinary itemsvalue per share-1.07-0.71-0.85-0.75
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.07-0.71-0.85-0.75